# Aegon (AEG)

Sector: Life insurance and retirement

| Field | Value |
|---|---|
| Price | $8.09 |
| Market cap | $13B |
| Intrinsic value source | Analysts |
| Data as of | 2026-11-20 |
| Next earnings | 2027-02-18 (confirmed) |

Analysts: Bullish

Picks: Research only

Discount category: Below intrinsic value

## In short

The market weighs the plan of Aegon to become a US life and retirement group against the cost and risk of the move, and growing free cash flow with a smooth move through 2027 can lift its value.

## Themes and gap

- Themes: Interest rates (interest-rates), New management (management-change), Regulation and courts (regulation-legal)
- Gap type: Can close (closable)
- Why: The completion of the Aegon UK sale, expected around the end of 2026, and the second half 2026 results on February 18, 2027 show whether free cash flow grows as planned.

## About

Aegon Ltd. (Aegon) is a financial services holding company. It is domiciled in Bermuda and has its head office in Schiphol, the Netherlands. Its main business is Transamerica, which sells life insurance, annuities and retirement plans in the United States, also through World Financial Group, a network of more than 100,000 agents. It also owns Aegon Asset Management, has insurance joint ventures in Spain and Portugal, China and Brazil, and holds shares in a.s.r., a Dutch insurer. Aegon agreed in April 2026 to sell Aegon UK to Standard Life. The operating result was EUR 804 million in the first half of 2026. Aegon reports in euros under IFRS and files 20-F and 6-K reports. Its common shares trade on Euronext Amsterdam in euros, and its New York Registry Shares, one per common share, trade on the NYSE in US dollars.

## Thesis

The price of Aegon depends on whether it can become a US life insurance and retirement group that earns steady cash, after it moves its legal seat to the United States. Shareholders approved the move at the meeting on October 8, 2026, and Vereniging Aegon exchanged its Common Shares B for common shares, so Aegon now has one class of shares. The move to Delaware, as Transamerica Inc., is expected on or about January 1, 2028, and Aegon plans to report under US GAAP from the full-year 2027 results. Aegon aims to grow free cash flow by about 5% a year from about EUR 0.68 billion in 2025, and it returns cash through dividends and buybacks. For the price to hold or rise, four things must be true. Transamerica must keep growing life and retirement sales with stable capital ratios. The sale of Aegon UK must complete around the end of 2026. The change to US GAAP must not show much lower earnings or equity. Free cash flow and dividends must grow as planned. The second half 2026 results on February 18, 2027 are the next test.

## Checkpoints

- Dec 2026 (estimate): Sale of Aegon UK completes. Status: Pending. Watch: The sale of Aegon UK to Standard Life completes around the end of 2026, as Aegon expects, and this passes; a delay past March 2027 or a lower price fails.
- Feb 18, 2027: Second half 2026 results. Status: Pending. Watch: Free cash flow for 2026, without Aegon UK, is in line with growth of about 5% a year from EUR 0.68 billion and the dividend per share grows more than 5%, and this passes; lower free cash flow or a smaller dividend increase fails.

## Balance sheet

- Cash: €1.7B
- Debt: €5.0B
- Net debt: €3.3B

At June 30, 2026, Aegon had Cash Capital at Holding of EUR 1.7 billion, above its operating range, and it aims to reduce it to around EUR 1.0 billion by the end of 2026 through buybacks. Gross financial leverage was EUR 4,967 million, a gross financial leverage ratio of 26.0%, and it includes senior debt and subordinated and perpetual securities. In the first half of 2026 Aegon issued USD 500 million of senior notes that trade on the NYSE and bought back some subordinated notes. The Group solvency ratio was 169% and the US risk-based capital ratio was 420%, above its operating level of 400%. Shareholders' equity was EUR 7.3 billion, and valuation equity, which adds the contractual service margin after tax, was EUR 14.0 billion, or EUR 9.42 per share.

As of 2026-06-30.

Sources:

- https://www.sec.gov/Archives/edgar/data/769218/000119312526357694/d131063d6k.htm
- https://www.sec.gov/Archives/edgar/data/769218/000119312526357707/d115717d6k.htm

## Dividends

- Dividend yield: 6.1% (last 12 months, at the current price)
- Paid per share, last 12 months: $0.493 (2 payments)
- Current annual rate: $0.493 (the last two payments)
- Latest ex-dividend date: 2026-09-03, $0.246 per share

Dividends per share by year: 2016: $0.288, 2017: $0.299, 2018: $0.165, 2019: $0.333, 2020: $0.071, 2021: $0.166, 2022: $0.206, 2023: $0.28, 2024: $0.349.

Some payments of 2025 are missing in the data, so no bar is shown for that year.

Source: company filings and market data, read on 2026-11-12.

## Recent events

- 2026-10-15: Aegon repurchased all Common Shares B held by Vereniging Aegon Americas in exchange for common shares on a 40-to-1 basis. The voting rights agreement and call option of the Vereniging ended, and interim bye-laws in line with US practice became effective.
- 2026-10-08: Shareholders at the Extraordinary General Meeting approved the move of Aegon's legal seat to the United States, where it will become Transamerica Inc., a Delaware company, and a new Omnibus Incentive Plan.
- 2026-08-20: Aegon reported first half 2026 results. The operating result rose 9% to EUR 804 million and the net result was EUR 608 million. Free cash flow was EUR 392 million. It declared an interim dividend of EUR 0.21 per share, up 11%, and increased its second half buyback to EUR 350 million.
- 2026-08-20: Aegon said that Duncan Russell will step down as Chief Financial Officer and leave the company in April 2027, in connection with the move to the United States.
- 2026-04-15: Aegon agreed to sell Aegon UK to Standard Life for a total of GBP 2.0 billion: 181 million shares of Standard Life, worth GBP 1.25 billion at the announcement, and GBP 649 million in cash. Completion is expected around the end of 2026.

## Latest news and filings

- Last earnings: 2026-08-20
- Next earnings: 2027-02-18 (confirmed by the company)

| Filed | Form | Headline | Period end | XBRL document | Link |
| --- | --- | --- | --- | --- | --- |
| 2026-08-20 | 6-K | Interim report for the period ended Jun 30, 2026 | 2026-06-30 |  | https://www.sec.gov/Archives/edgar/data/769218/000119312526357707/d115717d6k.htm |
| 2026-03-26 | 20-F | Annual report for the period ended Dec 31, 2025 | 2025-12-31 |  | https://www.sec.gov/Archives/edgar/data/769218/000119312526124987/d29563d20f.htm |
| 2025-03-27 | 20-F | Annual report for the period ended Dec 31, 2024 | 2024-12-31 |  | https://www.sec.gov/Archives/edgar/data/769218/000119312525064638/d869711d20f.htm |

Every filing on SEC EDGAR (CIK 769218): https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000769218&type=&dateb=&owner=include&count=40

## Risks

- Medium: The move to the United States is complex. It needs the Bermuda discontinuance and other steps until about January 1, 2028, and the change to US GAAP can change reported earnings and equity.
- Medium: Markets move capital. The US risk-based capital ratio was 420% at June 30, 2026, and lower equity markets, credit losses or interest rate moves can cut capital generation, as market movements did by EUR 146 million in the first half.
- Medium: Policyholder behavior can differ from assumptions. The annual assumption review in the first half of 2026 had an unfavorable impact of EUR 231 million on valuation equity.
- Medium: The sale of Aegon UK needs regulatory approvals, and part of the price is in Standard Life shares, whose value can fall.
- Low: Management changes. The CFO leaves in April 2027, and a new President and Chief Operating Officer starts on January 1, 2027.

## Links

- Page: https://picks.utilarium.app/company/AEG/
- History of changes: https://picks.utilarium.app/company/AEG/history/
- JSON with full history: https://picks.utilarium.app/data/company/AEG.json

> Picks is a personal record of stock picks. It gives general opinions about stocks, including a "Top pick" label. They are not tailored to your needs, goals or risk tolerance. Kevin is not a registered adviser and relies on the general-advice exemption in Canadian securities law (NI 31-103 s.8.25). Do your own research, or ask a registered adviser. Kevin may hold any stock on this site. Prices, intrinsic values and ratings can be delayed or wrong; check the original source. Full disclaimer: /disclaimer/.
